Trial · NCT03688971
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seborrheic dermatitis area severity index (SDASI) | 6 Weeks | Assessment of erythema, scales and papules and each are scored as 0=none to 3=severe. |
| Primary | Investigator global assessment (IGA) | 6 Weeks | This is a 5-point scale ranging from 0=clear to 4=severe. |
| Primary | Area of involvement | 6 Weeks | Facial area involvement is estimated as a % of the body surface area (BSA) |
| Primary | Patient Reported Outcome (PRO) - eDiary | 4 Weeks | Single-question assessment regarding patient's worst itch. On a scale of 0-100, 0=no itch and 100=worst itch. |
| Primary | PRO - 5-D itch scale | 6 Weeks | Multidimensional measure of itching. Covers 5 domains: duration, degree, direction, disability and distribution. |
| Primary | PRO - dermatology life quality index (DLQI) | 6 Weeks | Asses health-related quality of life in general dermatology disability index |
| Primary | Standardized photography | 6 Weeks | Facial photographs will be taken by a 2D camera (VISIA-CR) |
| Primary | Sebum measurements | 6 Weeks | Measurement of sebum excretion by Sebumeter |
| Primary | Trans Epidermal Water Loss (TEWL) | 6 Weeks | To assess barrier status of lesional and non-lesional skin. |
| Primary | Optical Coherence Tomography (OCT) | 6 Weeks | Measurement of cutaneous morphology of seborrheic dermatitis |
| Primary | Liquid chromatography-mass spectrometry (LC-MS) | 6 Weeks | Will evaluate the changes in lipid composition of stratum corneum (SC). |
| Secondary | Skin microbiota | 6 Weeks | collection of skin culture sample to evaluate skin microbiota |
| Secondary | Skin mycobiota | 6 Weeks | collection of skin culture sample to evaluate skin mycobiota |
| Secondary | Faecal microbiome | 4 Weeks | collection of faecal samples to evaluate faecal microbiome |
| Secondary | Adverse events collected throughout the study | 6 Weeks | |
| Secondary | Vital signs performed at screening and end of study | 6 Weeks | Evaluation of systolic and diastolic blood pressure |
| Secondary | Vital signs performed at screening and end of study | 6 Weeks | Evaluation of pulse rate |
| Secondary | Vital signs performed at screening and end of study | 6 Weeks | Evaluation of temperature |
| Secondary | 12-Lead ECGs performed at screening and end of study | 6 Weeks | Assessment of heart rate |
| Secondary | 12-Lead ECGs performed at screening and end of study | 6 Weeks | Assessment of PR, QRS, QT, QTcB and QTcF |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03688971/registered